LONG-TERM URINARY TOXICITY AFTER 3-DIMENSIONAL CONFORMAL RADIOTHERAPY FOR PROSTATE CANCER IN PATIENTS WITH PRIOR HISTORY OF TRANSURETHRAL RESECTION
|
|
- Loren Hopkins
- 8 years ago
- Views:
Transcription
1 PII S (00) Int. J. Radiation Oncology Biol. Phys., Vol. 48, No. 3, pp , 2000 Copyright 2000 Elsevier Science Inc. Printed in the USA. All rights reserved /00/$ see front matter CLINICAL INVESTIGATION Prostate LONG-TERM URINARY TOXICITY AFTER 3-DIMENSIONAL CONFORMAL RADIOTHERAPY FOR PROSTATE CANCER IN PATIENTS WITH PRIOR HISTORY OF TRANSURETHRAL RESECTION AJAYPAL S. SANDHU, M.D., D.M.R.T., MICHAEL J. ZELEFSKY, M.D., HENRY J. LEE, M.D., PH.D., DANNA LOMBARDI, B.A., ZVI FUKS, M.D., AND STEVEN A. LEIBEL, M.D. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY Purpose: To report on the long-term urinary morbidity among prostate cancer patients with a prior history of a transurethral resection of the prostate (TURP) treated with high-dose 3-dimensional conformal radiotherapy (3D-CRT). Methods and Materials: Between 1988 and 1997, 1100 patients with clinically localized prostate cancer were treated with 3D-CRT. Of these, 120 patients (8%) were identified as having had a prior TURP and are the subjects of this analysis. The median age was 71 years (range: years). The clinical stages of the patients were T1c: 33 (28%); T2a: 38 (32%); T2b: 15 (13%); and T3: 34 (27%). Neoadjuvant androgen ablation therapy was given to 39 (33%). The median radiation dose prescribed to the planning target volume was 75.6 Gy (range: Gy). The median elapsed time from TURP to initiation of 3D-CRT was 69 months (range: months). The median follow-up time was 51 months (range: months). Results: Five patients of the 120 with a prior history of TURP (4%) developed a urethral stricture after 3D-CRT which was corrected with dilatation. The 5-year actuarial likelihood of > Grade 2 late urinary toxicities was 9%. No Grade 4 urinary toxicities were observed in this group of patients. Among 110 patients who were completely continent of urine prior to 3D-CRT, 10 (9%) developed stress incontinence requiring 1 pad daily for protection or experienced occasional leakage (not requiring pad protection). The 5-year incidence of > Grade 1 stress incontinence was 18% in patients who developed acute > Grade 2 GU symptoms during the course of 3D-CRT compared to 7% for patients who experienced Grade 1 or no acute urinary symptoms (p 0.05). The radiation dose (>75.6 Gy vs. <75.6 Gy), the number of prior TURP procedures, or the volume of resected tissue at the time of TURP had no significant impact on the long-term urinary morbidity outcome. A multivariate analysis demonstrated that the presence of Grade 2 acute urinary symptoms was the only predictor of > Grade 1 stress incontinence after 3D-CRT in this group of patients. Conclusions: Despite prior TURP, the incidence of > Grade 3 urinary toxicities is low. Nevertheless, especially among patients with a prior history of TURP who experience Grade 2 acute urinary symptoms during radiation treatment, a higher risk of stress incontinence is observed Elsevier Science Inc. Prostate cancer, Conformal radiotherapy, Transurethral resection, Toxicity. INTRODUCTION Reprint request to: Michael J. Zelefsky, M.D., Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY zelefskm@ mskcc.org Several reports have suggested a higher incidence of late urinary complications after external beam radiotherapy among patients who underwent a previous transurethral resection of prostate (TURP) (1 3). Higher rates of urinary toxicities in the setting of a prior TURP have also been reported after permanent interstitial implantation of the prostate (4, 5). Post-treatment complications have included chronic urethritis, stress incontinence, and in rare cases, fistula and necrosis. The likely mechanism of increased urinary toxicity in these patients is related to the relative devascularization of the urethra after TURP (6) and the decreased capability of the mucosa to repair sublethal damage after radiotherapy. Although a prior TURP does not constitute a contraindication to radiotherapy, treatment must be undertaken in a cautious fashion. Because of the high central prostate doses achieved with brachytherapy, in particular, the risk of increased late urinary toxicity is well recognized. Limited information, however, is available regarding the outcome of such patients after high-dose conformal 3-dimensional radiotherapy (3D-CRT). Although the delivery of higher doses with conformal radiotherapy can compound the effect of previous TURP on urinary morbidity, the improved homogeneity of the dose distribution associated with 3D-CRT compared to conventional treatment techniques may reduce the expected late sequelae. In this paper, Accepted for publication 23 May
2 644 I. J. Radiation Oncology Biology Physics Volume 48, Number 3, 2000 we report the long-term urinary morbidity among 120 prostate cancer patients with a prior history of TURP treated to high-dose 3D-CRT. METHODS AND MATERIALS Between 1988 and 1998, 1100 patients with clinically localized prostate cancer were treated with 3D-CRT. Of these, 120 patients (11%) were identified as having had a prior TURP. The median age of the patients was 71 years (range; years). The American Joint Committee on Cancer (AJCC) 1997 clinical stage was T1c in 33 patients (28%), T2a in 38 (32%), T2b in 15 (13%), and T3 in 34 patients (27%). The technique of radiotherapy has been previously described in detail (7). In brief, the planning target volume (PTV) was derived from simulation CT scans and included the entire prostate and seminal vesicles plus a 1.0-cm margin, except at the prostate rectum interface where a 0.6-cm margin was used to decrease the risk of rectal toxicity. An additional 0.5-cm margin was added circumferentially around the clinical target volume (CTV) and 1.0 cm superiorly and inferiorly to account for penumbra of the radiation beams. Patients were immobilized and treated in the prone position as previously described (8). In general, treatments were delivered with six individually shaped coplanar fields, with MV X-rays in daily fractions of 1.8 Gy. More recently a five-field intensity-modulated treatment plan was used for patients treated to 81 Gy (9). Radiation doses were prescribed to the maximum isodose surface distribution that completely encompassed the PTV. A minimum tumor dose of 64.8 Gy was given to 18 patients (15%), 70.2 Gy to 37 (31%), 75.6 Gy to 48 (40%), and 81.0 Gy to 17 patients (14%). In general, the isocenter doses (ICRU prescription point) were 4 7% higher than the aforementioned prescription doses. Dose volume histograms were used to ensure that no more than 30% of the rectal wall and/or 50% of bladder wall received a maximum dose of 75.6 Gy. Thirty-nine patients (33%) with large-volume prostate glands, in whom the best feasible plan yielded dose volume histograms that exceeded these limits, were treated with a 3-month course of neoadjuvant androgen deprivation therapy to decrease the size of the prostatic target volume (10, 11). This treatment was continued throughout the course of radiotherapy and stopped at its completion. The median elapsed time from TURP to initiation of 3D-CRT was 69 months with a range of months. Thirty-nine patients (36%) had TURP within 3 years of 3D-CRT. Based on available information, extent and volume of TURP was estimated. TURP volume was described as minimal (volume 10 grams, biopsy or chips) in 38 (32%) patients, extensive (volume 10 grams) in 43 (36%), and unknown in the remaining 39 (32%). Twentyfive patients (23%) underwent 1 prior TURP procedure, and 95 (77%) underwent only one TURP before treatment. Acute reactions included those arising either during the course of treatment or within the first 90 days after its completion. Detailed toxicity data were prospectively collected by the treating physicians during the course of therapy and in the follow-up period. Acute toxicity was graded according to the most severe reaction observed at 2 or more consecutive weekly examinations. Follow-up evaluations after treatment were performed at 3- to 6-month intervals. Late complications were defined as those developing more than 90 days after the completion of irradiation or those that started during treatment and persisted for longer than 90 days after its completion. Acute and late toxicities were graded according to the Radiation Therapy Oncology Group morbidity scoring scale (12). The degree of stress incontinence after therapy was scored according to the Late Effects Normal Tissue/Radiation Therapy Oncology Group (LENT/ RTOG) classification (13). The median follow-up time was 51 months, ranging from months. Distribution of times to develop late toxicity was calculated according to the product-limit (Kaplan-Meier) method (14). Differences between time-adjusted incidence rates were evaluated using the Mantel log-rank test for censored data (15). The relative impact of covariates that affect time-adjusted outcomes (multivariate analysis) was determined using the stepwise Cox proportional hazards regression model (16). Late complications were determined as of the time of analysis in December RESULTS Overall, 84 of the 120 patients (70%) had no or only mild (Grade 1) acute GU toxicity not requiring any therapeutic intervention. Medications were required for relief of acute GU-related symptoms (Grade 2) in 36 patients (30%). These symptoms included urinary frequency and urgency which in general improved with alpha blocker medications as previously reported (17). The 5-year actuarial likelihood of Grade 2 late urinary toxicities was 9% among patients with a prior history of TURP compared to 10% for patients with no history of TURP ( p 0.5). Five patients (4%) developed a urethral stricture after 3D-CRT, which was corrected with dilatation. As shown in Fig. 1, the 5-year actuarial likelihood of developing a urethral stricture was 4% compared to 1% for patients (n 980) who did not undergo a prior TURP ( p 0.01). No urinary toxicities occurred after 30 months from completion of 3D-CRT, and no Grade 4 urinary toxicities were observed. One hundred ten of the 120 patients (92%) were completely continent of urine prior to 3D-CRT. Of these, 2 (2%) developed stress incontinence requiring 1 pad daily for protection, and 8 (7%) experienced occasional leakage not requiring pad protection. The 5-year actuarial likelihood of Grade 1 stress incontinence development in this group was 9%. Among the 10 patients who had some form of urinary incontinence prior to 3D-CRT, one patient developed worsening of his incontinence after therapy whereas the remaining 9 patients experienced no significant changes in their
3 Conformal radiotherapy after TURP A. S. SANDHU et al. 645 Fig. 1. Actuarial incidence of urethral strictures after 3D-CRT among patients with and without a prior history of TURP. continence status. Patients who developed acute Grade 2 GU symptoms during the course of 3D-CRT were more likely to develop post-treatment urinary incontinence. As shown in Fig. 2, among patients who were continent prior to therapy but developed Grade 2 acute urinary symptoms during the course of 3D-CRT, the 5-year incidence of Grade 1 stress incontinence development was 18% compared to 7% for patients who experienced Grade 1 or no acute urinary symptoms ( p 0.05). A multivariate analysis demonstrated that the presence of Grade 2 acute urinary symptoms ( p 0.01; relative risk, 4.8) was the only predictor of Grade 1 stress incontinence in these patients. The radiation dose ( 75.6 Gy versus 75.6 Gy), volume of resected tissue at the time of TURP, and the number of prior TURP procedures had no significant impact on longterm urinary incontinence. DISCUSSION This report indicates that high-dose conformal radiotherapy is well tolerated among patients who previously underwent TURP. A small but significantly increased risk of urethral stricture development after 3D-CRT was observed for patients who underwent a prior TURP compared to those Fig. 2. Actuarial incidence of Grade 1 urinary incontinence among 110 TURP patients who were completely continent at baseline prior to 3D-CRT. A significant increase in incontinence was observed for those patients who experienced acute urinary symptoms during the course of 3D-CRT.
4 646 I. J. Radiation Oncology Biology Physics Volume 48, Number 3, 2000 who never underwent this procedure (4% versus 1%, respectively). Nevertheless, it remains unclear to what extent 3D-CRT increases the risk of stricture development among patients who previously underwent TURP compared to similar prior TURP patients who are not treated with 3D-CRT. Several reports have documented a 2 12% incidence of urethral strictures after TURP alone in patients who never underwent other therapy including surgery or radiotherapy (18 20). In our report, there was no significant increase in the incidence of urethral strictures among TURP patients who received high-dose 3D-CRT ( 75.6 Gy) compared to similar patients who received lower doses. Previous studies have reported a higher frequency of urethral toxicities for patients undergoing prior TURP after conventional radiotherapy (2, 6). Seymore et al. (6) reported statistically significant differences in the development of urethral strictures or bladder neck contractures after radiotherapy when comparing patients with prior TURP to no prior TURP (15% vs. 6% p 0.025). The higher incidence of stricture development in that study may be related to the relative close temporal relationship with the TURP procedure and the initiation of radiotherapy. In that study the majority of patients who developed complications underwent TURP within 33 days of treatment. The 4% incidence of urethral strictures in our study for patients with a prior history of TURP is similar to the rates reported by Perez et al. and Lawton et al. in similar patients (2, 12). These lower rates may be attributed to the increased elapsed time between TURP and initiation of radiation treatment. In our study, the median time elapsed between TURP and initiation of treatment was greater than 5 years. Second, the use of conformal 3D- CRT in our study with associated improved homogeneity of the dose distribution could also have contributed to a lower incidence of urethral strictures despite the higher radiation doses routinely used. This report also confirms the findings of others concerning the increased risk of urinary incontinence following radiation therapy among patients who underwent prior TURP. At least two other studies (1, 2) have reported a higher incidence of urinary incontinence for patients with a history of prior TURP following external beam radiotherapy. Lee et al. (1) observed a higher urinary incontinence (Grade 2 or 3) rate of 2% in patients undergoing prior TURP compared to 0.2% in patients without prior TURP. A history of prior TURP was the only factor associated with a higher risk of this sequela. In our report, although no patient developed Grade 3 or 4 incontinence according to the LENT scale, a 9% incidence of Grade 1 incontinence was observed among 110 patients who were completely continent before the initiation of 3D-CRT. We also noted a higher incidence of post-treatment urinary incontinence among prior TURP patients who experienced acute Grade 2 urinary symptoms during 3D-CRT. These findings are consistent with previously reported results from our institution and others demonstrating increased long-term urinary toxicities among patients who experienced acute urinary symptoms during the course of radiotherapy (21, 22). In conclusion, these data suggest that despite a previous history of TURP, the risk of severe long-term urinary toxicities is relatively minimal after 3D-CRT and may be lower than what could be observed for similar patients after brachytherapy. Several reports have suggested higher risks of Grade 3 urinary toxicities among patients with an antecedent history of TURP who are treated with brachytherapy (4, 5). Zelefsky and Whitmore (23) reported on the 10-year urinary morbidity outcome after retropubic I-125 implantation among patients who underwent a prior TURP. In that report the incidence of Grade 2 or higher late urinary toxicities among treated patients with a prior TURP was 19% compared to 11% for patients without a history of TURP ( p 0.001). Blasko et al. (4) reported a 17% rate of incontinence and observed in some patients urethral necrosis among patients treated with a prior TURP. The higher urinary toxicity rates observed in TURP patients may be attributed to the expected increased central doses with this form of therapy. On the other hand, Wallner et al. (24) reported a significantly lower risk of late urethral toxicities after brachytherapy in a select group of patient who underwent a prior TURP. These authors speculated that lower complication rates may be more likely associated with peripheral-based seed loading schemes, and the avoidance of implantation in patients with large TURP defects. Nevertheless, in the absence of long-term toxicity outcome reports, brachytherapy for patients with a prior TURP should be performed with caution as inevitably doses in excess of the prescription doses are routinely delivered to the urethra and long-term toxicity could be higher than expected compared to patients undergoing 3D-CRT. REFERENCES 1. Lee WR, Schultheiss TE, Hanlon AL, Hanks GE. Urinary incontinence following external-beam radiotherapy for clinically localized prostate cancer. Urology 1996;48: Perez CA, Lee HK, Georgiou A, Lockett MA. Technical factors affecting morbidity in definitive irradiation for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1994;28: Green N, Treible D, Wallack H. Prostate cancer: Postirradiation incontinence. J Urol 1990;144: Blasko JC, Ragde H, Grimm PD. Transperineal ultrasoundguided implantation of the prostate: Morbidity and complications. Scand J Urol Nephrol Suppl 1991;137: Zelefsky MJ, Whitmore WW Jr, Leibel SA, Wallner KL, Fuks Z. Impact of TURP on the long term outcome of patients with prostatic carcinoma. J Urol 1993;150: Seymore CH, El-Mahdi AM, Schellhammer PF. The effect of prior transurethral resection of the prostate on post radiation urethral strictures and bladder neck contractures. Int J Radiat Oncol Biol Phys 1986;12: Leibel SA, Zelefsky MJ, Kutcher GJ, Burman CM, Mohan R,
5 Conformal radiotherapy after TURP A. S. SANDHU et al. 647 Mageras GS, Ling CC, Fuks Z. The biological basis and clinical application of three dimensional conformal external beam radiation therapy in carcinoma of the prostate. Semin Oncol 1994;21: Zelefsky MJ, Happersett L, Leibel SA, Burman CM, Schwartz L, Dicker AP, Kutcher GJ, Fuks Z. The effect of treatment positioning on normal tissue dose. Int J Radiat Oncol Biol Phys 1997;37: Zelefsky MJ, Fuks Z, Happersett L, et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radioth Oncol 2000;55: Zelefsky MJ, Leibel SA, Burman CM, Kutcher GJ, Harrison A, Happersett L, Fuks Z. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 1994;29: Zelefsky MJ, Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: Reducing the potential morbidity of therapy. Urol 1997;49: Lawton CA, Won M, Pilepich MV, Asbell SO, Shipley WU, Hanks GE, Cox JD, Perez CA, Sause WT, Doggett SRL, Rubin P. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and Int J Radiat Oncol Biol Phys 1991;21: Marks LB, Carroll PR, Dugan TC, Anscher MS. The response of the urinary bladder, urethra and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys 1995;31: Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: Mantel N. Evaluation of survival data and two rank order statistics arising in its consideration. Cancer Chem Reports 1966;50: Cox DR. Regression models and life tables. J Roy Statist Soc (Series B) 1972;34: Zelefsky MJ, Ginor RX, Fuks Z, Leibel SA. Efficacy of selective alpha-1 blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 1999;45: Chilton CP, Morgan RJ, England HR, Paris AMI, Blandy JP. A critical evaluation of the results of transurethral resection of the prostate. Br J Urol 1978;50: Meyhoff HH, Nordling J. Long term results of transurethral and transvesical prostatectomy: A randomized study. Scan J Urol Nephrol 1986;20: Hart AJL, Fowler JW. Incidence of urethral stricture after transurethral resection of the prostate. Urol 1981;18: Zelefsky MJ, Cowen D, Fuks Z, Shike M, Burman C, Jackson A, Venkatraman ES, Leibel SA. Long-term tolerance of highdose three dimensional conformal radiotherapy in patients with localized prostate cancer. Cancer 1999;85: Schulheiss TE, Lee WR, Hunt MA, Hanlon AL, Peter RS, Hanks GE. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1997;37: Zelefsky MJ, Whitmore WF. Long-term results of retropubic permanent I-125 implantation of the prostate for clinically localized prostate cancer. J Urol 1997;158: Wallner K, Lee H, Wasserman S, Dattoli M. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int J Radiat Oncol Biol Phys 1997;37:
LATE MORBIDITY PROFILES IN PROSTATE CANCER PATIENTS TREATED TO 79 84 GY BY A SIMPLE FOUR-FIELD COPLANAR BEAM ARRANGEMENT
PII S0360-3016(02)03822-1 Int. J. Radiation Oncology Biol. Phys., Vol. 55, No. 1, pp. 71 77, 2003 Copyright 2003 Elsevier Science Inc. Printed in the USA. All rights reserved 0360-3016/03/$ see front matter
More informationProstate IMRT: Promises and Problems Chandra Burman, Ph.D. Memorial Sloan-Kettering Cancer Center, New York, NY 10021
Prostate IMRT: Promises and Problems Chandra Burman, Ph.D. Memorial Sloan-Kettering Cancer Center, New York, NY 10021 Introduction Prostate is one of the treatment sites that is well suited for IMRT. For
More informationPROTON THERAPY FOR PROSTATE CANCER: THE INITIAL LOMA LINDA UNIVERSITY EXPERIENCE
doi:10.1016/j.ijrobp.2003.10.011 Int. J. Radiation Oncology Biol. Phys., Vol. 59, No. 2, pp. 348 352, 2004 Copyright 2004 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/04/$ see front
More informationMichael J. Zelefsky,*, Heather Chan, Margie Hunt, Yoshiya Yamada, Alison M. Shippy and Howard Amols
Long-Term Outcome of High Dose Intensity Modulated Radiation Therapy for Patients With Clinically Localized Prostate Cancer Michael J. Zelefsky,*, Heather Chan, Margie Hunt, Yoshiya Yamada, Alison M. Shippy
More informationPROSTATE CANCER WITH LARGE GLANDS TREATED WITH 3- DIMENSIONAL COMPUTERIZED TOMOGRAPHY GUIDED PARARECTAL BRACHYTHERAPY: UP TO 8 YEARS OF FOLLOWUP
0022-5347/03/1694-1331/0 Vol. 169, 1331 1336, April 2003 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000055773.91290.e8 PROSTATE CANCER
More informationRadiation Therapy for Prostate Cancer: Treatment options and future directions
Radiation Therapy for Prostate Cancer: Treatment options and future directions David Weksberg, M.D., Ph.D. PinnacleHealth Cancer Institute September 12, 2015 Radiation Therapy for Prostate Cancer: Treatment
More informationCYBERKNIFE RADIOSURGERY FOR EARLY PROSTATE CANCER Rationale and Results. Alan Katz MD JD Flushing, NY USA
CYBERKNIFE RADIOSURGERY FOR EARLY PROSTATE CANCER Rationale and Results Alan Katz MD JD Flushing, NY USA Prostate Ablative Therapy Over the last 10 years our therapy has improved bned rates for LDR/HDR
More informationBrachytherapy for prostate cancer
Brachytherapy for prostate cancer Findings by SBU Alert Published Jun 7, 2000 Version 1 Brachytherapy is not widely used in Sweden to treat localized prostate cancer. This treatment method has been available
More informationBard: Prostate Cancer Treatment. Bard: Pelvic Organ Prolapse. Prostate Cancer. An overview of. Treatment. Prolapse. Information and Answers
Bard: Prostate Cancer Treatment Bard: Pelvic Organ Prolapse Prostate Cancer An overview of Pelvic Treatment Organ Prolapse Information and Answers A Brief Overview Prostate Anatomy The prostate gland,
More informationCorporate Medical Policy Intensity-Modulated Radiation Therapy (IMRT) of the Prostate
Corporate Medical Policy Intensity-Modulated Radiation Therapy (IMRT) of the Prostate File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_the_prostate
More informationNATURAL HISTORY OF CLINICALLY STAGED LOW- AND INTERMEDIATE-RISK PROSTATE CANCER TREATED WITH MONOTHERAPEUTIC PERMANENT INTERSTITIAL BRACHYTHERAPY
doi:1.116/j.ijrobp.9..1 Int. J. Radiation Oncology Biol. Phys., Vol. 76, No., pp. 349 354, 1 Copyright Ó 1 Elsevier Inc. Printed in the USA. All rights reserved 36-316/1/$ see front matter CLINICAL INVESTIGATION
More informationThe optimal treatment for clinically localized
REVIEW COMBINING EXTERNAL BEAM RADIOTHERAPY WITH PROSTATE BRACHYTHERAPY: ISSUES AND RATIONALE CLARISSA FEBLES AND RICHARD K. VALICENTI The optimal treatment for clinically localized prostate cancer remains
More informationFIVE-YEAR BIOCHEMICAL OUTCOME FOLLOWING PERMANENT INTERSTITIAL BRACHYTHERAPY FOR CLINICAL T1 T3 PROSTATE CANCER
PII S0360-3016(01)01594-2 Int. J. Radiation Oncology Biol. Phys., Vol. 51, No. 1, pp. 41 48, 2001 Copyright 2001 Elsevier Science Inc. Printed in the USA. All rights reserved 0360-3016/01/$ see front matter
More informationRadiation Therapy in Prostate Cancer Current Status and New Advances
Radiation Therapy in Prostate Cancer Current Status and New Advances Arno J. Mundt MD Professor and Chairman Dept Radiation Oncology Moores Cancer Center UCSD Radiation Therapy Wilhelm Roentgen (1845-1923)
More informationImplementation Date: April 2015 Clinical Operations
National Imaging Associates, Inc. Clinical guideline PROSTATE CANCER Original Date: March 2011 Page 1 of 5 Radiation Oncology Last Review Date: March 2015 Guideline Number: NIA_CG_124 Last Revised Date:
More informationProton Therapy for Prostate Cancer
Proton Therapy for Prostate Cancer Andrew K. Lee, MD, MPH Director, Proton Therapy Center Associate Professor Department of Radiation Oncology M.D. Anderson Cancer Center Randomized studies showing benefit
More informationRadiation Therapy in Prostate Cancer Current Status and New Advances
Radiation Therapy in Prostate Cancer Current Status and New Advances Arno J. Mundt MD Professor and Chairman Dept Radiation Oncology Moores Cancer Center UCSD Presentation Welcome Overview of UCSD, Moores
More informationThe Science behind Proton Beam Therapy
The Science behind Proton Beam Therapy Anthony Zietman MD Shipley Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School Principles underlying Radiotherapy Radiation related
More informationThese rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.
Prostate Cancer OVERVIEW Prostate cancer is the second most common cancer diagnosed among American men, accounting for nearly 200,000 new cancer cases in the United States each year. Greater than 65% of
More informationradiotherapy in locally advanced prostatic cancer: A dosimetric point of view
Radiotherapy and Oncology 78 (2006) 47 52 www.thegreenjournal.com Prostate brachytherapy 192 Ir or 125 I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer:
More information馬 偕 紀 念 醫 院 新 竹 分 院 前 列 腺 癌 放 射 治 療 指 引
馬 偕 紀 念 醫 院 新 竹 分 院 前 列 腺 癌 放 射 治 療 指 引 2009.12.02 修 訂 2013.05.13 四 版 前 言 新 竹 馬 偕 醫 院 放 射 腫 瘤 科 藉 由 跨 院 聯 合 會 議 機 制 進 行 討 論, 以 制 定 符 合 現 狀 之 前 列 腺 癌 放 射 治 療 指 引 本 院 前 列 腺 癌 放 射 治 療 指 引 的 建 立, 係 參 考 國 內
More informationClinical Trials and Radiation Treatment. Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto
Clinical Trials and Radiation Treatment Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto What I will cover.. A little about radiation treatment The clinical trials
More informationExternal-Beam Radiotherapy in the Management of Carcinoma of the Prostate
Technological advances in external-beam radiation therapy and the developments in equipment and computers allow for safer delivery of higher radiation doses to the prostate. Tina Sotis. The Tropic of Capricorn
More informationProtons vs. CyberKnife. Protons vs. CyberKnife. Page 1 UC SF. What are. Alexander R. Gottschalk, M.D., Ph.D.
Protons vs. CyberKnife UC SF Protons vs. CyberKnife UC SF Alexander R. Gottschalk, M.D., Ph.D. Associate Professor and Director of the CyberKnife Radiosurgery Program Department of Radiation Oncology University
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationProstate Cancer with Bone Metastasis: the Consideration of Radiotherapy
Prostate Cancer with Bone Metastasis: the Consideration of Radiotherapy Case Number: RT2009-19(M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor Purpose: to present a case
More informationAmerican College Of Radiology ACR Appropriateness Criteria PERMANENT SOURCE BRACHYTHERAPY FOR PROSTATE CANCER
American College Of Radiology ACR Appropriateness Criteria PERMANENT SOURCE BRACHYTHERAPY FOR PROSTATE CANCER Expert Panel on Radiation Oncology Prostate Work Group: Louis Potters, MD 1 ; Carlos A. Perez,
More informationPrognostic Factors for Late Urinary Toxicity Grade 2-3 after Conformal Radiation Therapy on Patients with Prostate Cancer
Clinical Urology Toxicity Grade - after Radiation for Prostate Cancer International Braz J Urol Vol. (5): 65-661, September - October, 007 Prognostic Factors for Late Urinary Toxicity Grade - after Conformal
More informationThe Evolving Role of Prostate Brachytherapy
Brachytherapy is rapidly becoming a preferred choice by patients for the management of their localized prostate cancer. Faith Krucina. Power of Sound. 36 24. Acrylic on canvas, Courtesy of Artistic Images
More informationPSA Screening for Prostate Cancer Information for Care Providers
All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits
More information2/14/09. Long Term Risk of Radiation Therapy for Clinically Localized Prostate Cancer. Radiation Therapy: Various Forms of Radiation Treatment
Radical ctomy (surgery) Mack Roach III MD Professor & Chair Department of Radiation Oncology Long Term Risk of Radiation Therapy for Clinically Localized Cancer Radiation Therapy: Hormonal Therapy Cryotherapy
More informationProstate Cancer Treatment: What s Best for You?
Prostate Cancer Treatment: What s Best for You? Prostate Cancer: Radiation Therapy Approaches I. Choices There is really a variety of options in prostate cancer management overall and in radiation therapy.
More informationTransition from 2D to 3D Brachytherapy in Cervical Cancers: The Vienna Experience. Richard Pötter MD. BrachyNext, Miami, 2014.
Transition from 2D to 3D Brachytherapy in Cervical Cancers: The Vienna Experience Richard Pötter MD BrachyNext, Miami, 2014 Disclosures Richard Pötter, MD, does not have any financial relationships or
More informationSECOND MALIGNANCIES AFTER PROSTATE BRACHYTHERAPY: INCIDENCE OF BLADDER AND COLORECTAL CANCERS IN PATIENTS WITH 15 YEARS OF POTENTIAL FOLLOW-UP
doi:10.1016/j.ijrobp.2006.05.016 Int. J. Radiation Oncology Biol. Phys., Vol. 66, No. 3, pp. 669 673, 2006 Copyright 2006 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/06/$ see front
More informationRadiation therapy is a well-established treatment option for patients with
Hematol Oncol Clin N Am 20 (2006) 857 878 HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA Update on Radiation Therapy in Prostate Cancer Andrew K. Lee, MD, MPH*, Steven J. Frank, MD Division of Radiation
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationSRO Tutorial: Prostate Cancer Treatment Options
SRO Tutorial: Prostate Cancer Treatment Options May 7th, 2010 Daniel M. Aebersold Klinik und Poliklinik für Radio-Onkologie Universität Bern, Inselspital Is cure necessary in those in whom it may be possible,
More informationJAMA. 1998;280:969-974
Original Contributions Biochemical Outcome After Radical Prostatectomy, Radiation Therapy, or Interstitial for Clinically Localized Prostate Cancer Anthony V. D Amico, MD, PhD; Richard Whittington, MD;
More informationA918: Prostate: adenocarcinoma
A918: Prostate: adenocarcinoma General facts of prostate cancer The prostate is about the size of a walnut. It is just below the bladder and in front of the rectum. The tube that carries urine (the urethra)
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationProstate Cancer Treatment
Scan for mobile link. Prostate Cancer Treatment Prostate cancer is a tumor of the prostate gland, which is located in front of the rectum and below the bladder. Your doctor may perform a physical exam,
More informationTable of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation
More informationFAQ About Prostate Cancer Treatment and SpaceOAR System
FAQ About Prostate Cancer Treatment and SpaceOAR System P. 4 Prostate Cancer Background SpaceOAR Frequently Asked Questions (FAQ) 1. What is prostate cancer? The vast majority of prostate cancers develop
More informationHow To Know If You Should Get A Brachytherapy Or Radioactive Seed Implantation
MEDICAL POLICY SUBJECT: BRACHYTHERAPY OR PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy
More informationMedical Policy Brachytherapy for Clinically Localized Prostate Cancer Using Permanently Implanted Seeds
Medical Policy Brachytherapy for Clinically Localized Prostate Cancer Using Permanently Implanted Seeds Table of Contents Policy: Commercial Coding Information Information Pertaining to All Policies Policy:
More informationdoi:10.1016/j.ijrobp.2006.07.1382 CLINICAL INVESTIGATION
doi:10.1016/j.ijrobp.2006.07.1382 Int. J. Radiation Oncology Biol. Phys., Vol. 67, No. 1, pp. 57 64, 2007 Copyright 2007 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/07/$ see front matter
More informationPSA After Radiation for Prostate Cancer
Review Article [1] May 01, 2004 By Deborah A. Kuban, MD [2], Howard D. Thames, PhD [3], and Larry B. Levy, MS [4] The introduction of prostate-specific antigen (PSA) as a reliable tumor marker for prostate
More informationCyberknife Information Guide. Prostate Cancer Treatment
Cyberknife Information Guide Prostate Cancer Treatment CYBERKNIFE INFORMATION GUIDE PROSTATE CANCER TREATMENT As a patient recently diagnosed with localized prostate cancer, it is important that you familiarize
More informationProton Therapy for Prostate Cancer: Your Questions, Our Answers.
Proton Therapy for Prostate Cancer: Your Questions, Our Answers. When you re looking for the right treatment for your prostate cancer, nothing s more important than accurate information. Read on, and learn
More informationRadiation Therapy for Prostate Cancer
Radiation Therapy for Prostate Cancer Introduction Cancer of the prostate is the most common form of cancer that affects men. About 240,000 American men are diagnosed with prostate cancer every year. Your
More informationTime course of late rectal toxicity after radiation therapy for prostate cancer
(2010) 13, 138 143 & 2010 Nature Publishing Group All rights reserved 1365-7852/10 ORIGINAL ARTICLE www.nature.com/pcan Time course of late rectal toxicity after radiation therapy for prostate cancer K
More informationFactors influencing late rectal toxicity after radical radiotherapy of localized and locally advanced prostate cancer Research Article
Cancer Therapy Vol 5, page 253 Cancer Therapy Vol 5, 253-260, 2007 Factors influencing late rectal toxicity after radical radiotherapy of localized and locally advanced prostate cancer Research Article
More informationNeoadjuvant hormonal therapy in prostate cancer impact of PSA level before radiotherapy
JBUON 2013; 18(4): 949-953 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Neoadjuvant hormonal therapy in prostate cancer impact of PSA level
More informationTreatment Options After Failure of Radiation Therapy A Review Daniel B. Rukstalis, MD
MANAGEMENT OF RADIATION FAILURE IN PROSTATE CANCER Treatment Options After Failure of Radiation Therapy A Review Daniel B. Rukstalis, MD Division of Urology, MCP Hahnemann University, Philadelphia, PA
More informationURODYNAMIC CHANGES AT 18 MONTHS POST-THERAPY IN PATIENTS TREATED WITH EXTERNAL BEAM RADIOTHERAPY FOR PROSTATE CARCINOMA
PII S0360-3016(02)02726-8 Int. J. Radiation Oncology Biol. Phys., Vol. 53, No. 2, pp. 290 296, 2002 Copyright 2002 Elsevier Science Inc. Printed in the USA. All rights reserved 0360-3016/02/$ see front
More informationStomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda
Stomach (Gastric) Cancer Prof. M K Mahajan ACDT & RC Bathinda Gastric Cancer Role of Radiation Layers of the Stomach Mucosa Submucosa Muscularis Serosa Stomach and Regional Lymph Nodes Stomach and Regional
More informationFocal therapy for prostate cancer: seriously or seriously? Disclosures
Focal therapy for prostate cancer: seriously or seriously? Mitchell Kamrava, MD Assistant Clinical Professor Department of Radiation Oncology University of California Los Angeles Disclosures Speaking honorarium
More informationIGRT. IGRT can increase the accuracy by locating the target volume before and during the treatment.
DERYA ÇÖNE RADIOTHERAPY THERAPIST ACIBADEM KOZYATAGI HOSPITAL RADIATION ONCOLOGY DEPARTMENT IGRT IGRT (image-guided radiation therapy) is a technique that reduces geometric uncertainties by considering
More informationPatient Selection for Prostate Brachytherapy
Patient Selection for Prostate Brachytherapy a report by Gregory S Merrick, MD 1, Wayne M Butler, PhD 1 and K ent E Wallner, MD 2 1. Schiffler Cancer Center and Wheeling Jesuit University, 2. Puget Sound
More informationProstate Cancer. What is prostate cancer?
Scan for mobile link. Prostate Cancer Prostate cancer is a tumor of the prostate gland, which is located in front of the rectum and below the bladder. Your doctor may perform a physical exam, prostate-specific
More informationRadiation therapy for clinically localized prostate cancer: Long term results of 469 patients from a single institution in the era of dose escalation
Original Article Radiation therapy for clinically localized prostate cancer: Long term results of 469 patients from a single institution in the era of dose escalation ABSTRACT Aims: The aim of the following
More informationTreatment and Surveillance of Non- Muscle Invasive Bladder Cancer
Treatment and Surveillance of Non- Muscle Invasive Bladder Cancer David Josephson, MD FACS Fellowship Director, Urologic Oncology and Robotic Surgery Program Staging Most important in risk assessment and
More informationTITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software.
SAMPLE CLINICAL RESEARCH APPLICATION ABSTRACT: TITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software. Hypothesis:
More informationRadiation Protection in Radiotherapy
Radiation Protection in Radiotherapy Albert Lisbona Medical Physics Department CLCC Nantes Atlantique 44805 Saint-Herblain France a-lisbona@nantes.fnclcc.fr Radiation therapy The lecture is oriented to
More informationForum. Advances in radiation therapy for prostate. cancer. Abstract. Radiation therapy for localised prostate. cancer
Advances in radiation therapy for prostate cancer Nitya Patanjali 1 and Scott Williams 2 1. Radiation Oncology, Sydney Cancer Centre, Royal Prince Alfred Hospital, Sydney. 2. Radiation Oncology, Peter
More informationintensity_modulated_radiation_therapy_imrt_of_abdomen_and_pelvis 11/2009 5/2016 5/2017 5/2016
Corporate Medical Policy Intensity Modulated Radiation Therapy (IMRT) of Abdomen File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_abdomen_and_pelvis
More informationProstate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40.
A.D.A.M. Medical Encyclopedia. Prostate cancer Cancer - prostate; Biopsy - prostate; Prostate biopsy; Gleason score Last reviewed: October 2, 2013. Prostate cancer is cancer that starts in the prostate
More informationCurrent and Future Trends in Proton Treatment of Prostate Cancer
Current and Future Trends in Proton Treatment of Prostate Cancer Reinhard W. Schulte Assistant Professor Department of Radiation Medicine Loma Linda University Medical Center Loma Linda, CA, USA Outline
More informationTherapies for Prostate Cancer and Treatment Selection
Prostatic Diseases Therapies for Prostate Cancer and Treatment Selection JMAJ 47(12): 555 560, 2004 Yoichi ARAI Professor and Chairman, Department of Urology, Tohoku University Graduate School of Medicine
More informationProstatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.
Adjuvante und Salvage Radiotherapie Ludwig Plasswilm Klinik für Radio-Onkologie, KSSG CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS 1983 1998 Clinical stage T1 and T2 Mean
More informationAnalysis of Set-up Errors during CT-scan, Simulation, and Treatment Process in Breast Cancer Patients
대한방사선종양학회지 2005;23(3):169~175 Analysis of Set-up Errors during CT-scan, Simulation, and Treatment Process in Breast Cancer Patients Department of Radiation Oncology, College of Medicine, Ewha Womans University
More informationAdjuvant radiation therapy for recurrent PSA after radical prostatectomy in T1±T2 prostate cancer
Adjuvant radiation therapy for recurrent after radical prostatectomy in T1±T2 prostate cancer Prostate Cancer and Prostatic Diseases (1998) 1, 321±325 ß 1998 Stockton Press All rights reserved 1365±7852/98
More informationSalvage Conformal Radiotherapy for Biochemical Recurrent Prostate Cancer after Radical Prostatectomy
Clinical Urology Salvage Conformal Radiotherapy for Prostate Cancer International Braz J Urol Vol. 32 (4): 46-427, July - August, 2006 Salvage Conformal Radiotherapy for Biochemical Recurrent Prostate
More informationEffective for dates of service on or after May 1, 2015 refer to: Blue Cross and Blue Shield of Alabama Radiation Therapy Management RTM Policies
Effective for dates of service on or after May 1, 2015 refer to: Blue Cross and Blue Shield of Alabama Radiation Therapy Management RTM Policies Name of Policy: Brachytherapy for Clinically Localized Prostate
More informationPrecise, Minimally Invasive Prostate Cancer Removal
Precise, Minimally Invasive Prostate Cancer Removal Learn why da Vinci Surgery may be your best treatment option 1 Beyond Minimally Invasive For Prostate Cancer 1 Facing Prostate Cancer Prostate cancer
More informationSubject: Proton Beam Therapy for Prostate Cancer
Subject: Proton Beam Therapy for Prostate Cancer Guidance Number: MCG-153 Revision Date(s): Original Effective Date: 10/30/13 Medical Coverage Guidance Approval Date: 10/30/13 PREFACE This Medical Guidance
More informationLocal Salvage Therapies After Failed Radiation for Prostate Cancer. Biochemical Failure after Radiation
Local Salvage Therapies After Failed Radiation for Prostate Cancer James Eastham, MD Memorial Sloan-Kettering Cancer Center New York, New York Biochemical Failure after Radiation ASTRO criteria 3 consecutive
More informationAnalysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data
The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500
More informationCMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014
Background CMScript Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014 Prostate cancer is second only to lung cancer as the leading cause of cancer-related deaths in men. It is
More informationPROTON BEAM THERAPY FOR PROSTATE CANCER. A Technology Assessment
PROTON BEAM THERAPY FOR PROSTATE CANCER A Technology Assessment INTRODUCTION The California Technology Assessment Forum is requested to review the scientific evidence for the use of proton therapy for
More informationHigh Intensity Focused Ultrasound for Prostate Cancer
High Intensity Focused Ultrasound for Prostate Cancer Patient Information Exploring a Minimally Invasive Prostate Cancer Therapy The Choice for HIFU Worldwide A Patient s Guide to Prostate Cancer and Sonablate
More informationProstate Cancer. Patient Information
Prostate Cancer Patient Information 1 The Prostate & Prostate Cancer The prostate is a small gland in the male reproductive system, approximately the size and shape of a walnut. It is located directly
More informationProstate Cancer Results Study Group 2014 Results Comparing Treatment of. About This Review Study
Prostate Cancer Results Study Group Results Comparing Treatment of Prostate Cancer Peter Grimm, DO Seattle, WA About This Review Study,000+ prostate studies were published between 00 and June 3, of those
More informationEarly Prostate Cancer: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Early Prostate Cancer:
More informationHematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer
Gurka et al. Radiation Oncology (2015) 10:44 DOI 10.1186/s13014-015-0351-6 RESEARCH Open Access Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer Marie
More informationTransrectal high-intensity focused ultrasound for the treatment of localized prostate cancer: Eight-year experience
International Journal of Urology (2009) 16, 881 886 doi: 10.1111/j.1442-2042.2009.02389.x Original Article: Clinical Investigationiju_2389 881..886 Transrectal high-intensity focused ultrasound for the
More informationTARGETED CRYOABLATION OF THE PROSTATE: 7-YEAR OUTCOMES IN THE PRIMARY TREATMENT OF PROSTATE CANCER
TARGETED CRYOABLATION OF THE PROSTATE: 7-YEAR OUTCOMES IN THE PRIMARY TREATMENT OF PROSTATE CANCER DUKE K. BAHN, FRED LEE, ROBERT BADALAMENT, ANIL KUMAR, JEFFREY GRESKI, AND MICHAEL CHERNICK ABSTRACT The
More informationMedical Marijuana Use in Patients with History of SCCHN Treated with Radiotherapy
HEALTH SERVICES RESEARCH Assessment the Impact of Real-time Tumor Tracking & Reduced Planning Target Volume Margins on Quality-of-Life in Prostate Cancer Patients Treatment with Intensity Modulated Radiotherapy
More informationNIA RADIATION ONCOLOGY CODING STANDARD. Dosimetry Planning
NIA RADIATION ONCOLOGY CODING STANDARD Dosimetry Planning CPT Codes: 77295, 77300, 77301, 77306, 77307, 77321, 77316, 77317, 77318, 77331, 77399 Original Date: April, 2011 Last Reviewed Date: November,
More informationPROSTATE CANCER. Get the facts, know your options. Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology
PROSTATE CANCER Get the facts, know your options Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology i What is the Prostate? Unfortunately, you have prostate
More informationBRACHYTHERAPY FOR TREATMENT OF BREAST CANCER
BRACHYTHERAPY FOR TREATMENT OF BREAST CANCER Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationTreating Localized Prostate Cancer A Review of the Research for Adults
Treating Localized Prostate Cancer A Review of the Research for Adults Is this information right for me? Yes, this information is right for you if: Your doctor * said all tests show you have localized
More informationGENERAL CODING. When you review old cases that were coded to unknown, make corrections based on guidelines in effect at the time of diagnosis.
GENERAL CODING When you review old cases that were coded to unknown, make corrections based on guidelines in effect at the time of diagnosis. Exception: You must review and revise EOD coding for prostate
More informationIntensity Modulated Radiation Therapy (IMRT) for Thyroid Cancer
Thyroid Science 5(1):CLS1-8, 2010 www.thyroidscience.com Clinical and Laboratory Studies Intensity Modulated Radiation Therapy (IMRT) for Thyroid Cancer 1 2 5 Aruna Turaka, MD, Tianyu Li, MS, Jian Q. Yu,
More informationEsperienza di stereotassia polmonare al Campus Bio-Medico: tecnica e risultati Rolando M. D Angelillo
Esperienza di stereotassia polmonare al Campus Bio-Medico: tecnica e risultati Rolando M. D Angelillo Università Campus Bio-Medico di Roma - Via Álvaro del Portillo, 21-00128 Roma Italia BED 10 > 100 Gy
More informationHEALTH NEWS PROSTATE CANCER THE PROSTATE
HEALTH NEWS PROSTATE CANCER THE PROSTATE Prostate comes from the Greek meaning to stand in front of ; this is very different than prostrate which means to lie down flat. The prostate is a walnut-sized
More informationBRACHYTHERAPY OR CONFORMAL EXTERNAL RADIOTHERAPY FOR PROSTATE CANCER: A SINGLE-INSTITUTION MATCHED-PAIR ANALYSIS
doi:10.1016/j.ijrobp.2009.01.081 Int. J. Radiation Oncology Biol. Phys., Vol. 76, No. 1, pp. 43 49, 2010 Copyright Ó 2010 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/10/$ see front
More informationIndividual Prediction
Individual Prediction Michael W. Kattan, Ph.D. Professor of Medicine, Epidemiology and Biostatistics, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Chairman, Department
More informationRe irradiation Using HDR Interstitial Brachytherapy for Locally Recurrent. Disclosure
Re irradiation Using HDR Interstitial Brachytherapy for Locally Recurrent Cervical lcancer Yasuo Yoshioka, MD Department of Radiation Oncology Osaka University Graduate School of Medicine Osaka, Japan
More information1 of 6 6/13/11 12:40 PM
ONCOLOGY. Vol. 25 No. 7 REVIEW ARTICLE Proton Therapy for Prostate Cancer By Bradford Hoppe, MD, MPH 1, Randal Henderson, MD, MBA 1, William M. Mendenhall, MD 1, Romaine C. Nichols, MD 1, Zuofeng Li, PhD
More information